You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Baseline Characteristics of the Study Participants

From: Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment

Variable Early therapy n = 88 Delayed therapy n = 62 P value
Age, years
Mean ± SD 34.86 ± 8.1 34.82 ± 7.6 0.97
Gender, number (%):
Male 74 (84.1%) 52 (83.9%)  
Female 14 (15.9%) 10 (16.1%) 0.971
BMI, kg/m2:
Mean ± SD 17.9 ± 2.8 18.4 ± 2.1  
Hemoglobin, mg/dl
Mean ± SD 10.6 ± 1.7 11.0 ± 1.9  
CD4 count, cells/mm3:
Median 133 152  
(Range) (7 – 588) ( 14 – 648 )  
log10viral load/ml:
Median 5.36 5.30  
(Range) (2.42–5.88) (2.33–5.88)  
Non TB OI’s :
number (%) 12 (13.6%) 10 (16.1%) 0.671
WHO Staging of HIV disease, number (%):
Stage 3 19(21.6%) 15 (24.2%) 0.70
Stage 4 69 (78.4%) 47 (75.8%) (overall)
Type of Tuberculosis, number (%):
PTB 19 (21.6%) 15 (24.2%)  
PTB with Dissemination 33 (37.5%) 26 (41.9%) 0.367
EPTB 18 (20.4%) 15 (24.2%) (overall)
EPTB with Dissemination 18 (20.4%) 06 (09.7%)  
DOTS Category of ATT, number (%):
Category I (2H3R3Z3E3 + 4H3R3) 83 (94.3%) 61 (98.4%) 0.214
Category II (2H3R3Z3E3S3 + 1H3R3Z3E3 + 5H3R3E3) 05 (5.7%) 01 (1.6%) (overall)
  1. SD = Standard deviation; BMI = Body Mass Index; OI’s = Opportunistic Infections; WHO = World Health Organization; HIV = Human immunodeficiency virus; PTB = Pulmonary Tuberculosis; EPTB = Extra Pulmonary Tuberculosis; ATT = Antituberculosis treatment; H = Isoniazid (600 mg), R = Rifampicin (450 mg), Z = Pyrazinamide (1500 mg), E = Ethambutol (1200 mg), S = Streptomycin (750 mg).